Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer

cascCascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor, in combination therapy at the European Society for Medical Oncology (ESMO) 2016 Congress being held October 7-11, 2016 in Copenhagen, Denmark.
Data from the poster presentation (#278 “Cutaneous Responses in HER2+ Metastatic Breast Cancer in Phase 1b Study of Tucatinib (ONT-380), an Oral HER2-Specific Inhibitor in Combination with Capecitabine and/or Trastuzumab in Third Line or Later Treatment”), reported on responses of skin lesions in HER2+ metastatic breast cancer patients following treatment with tucatinib in combination with capecitabine and/or trastuzumab.

“Data suggest that skin may be a sanctuary site for metastatic breast cancer similar to the brain and therefore poorly penetrated by drug therapies that could help control cancer,” commented Dr. Alison Conlin, study author and Medical Oncologist at Providence Cancer Center, Portland, OR. “As a result, any meaningful improvement in patients’ skin metastases would be a welcome development, particularly given the morbidity that these skin metastases cause. Tucatinib, when used in combination, appears to show early evidence of activity in treating cutaneous HER2+ metastases, a common yet difficult-to-treat aspect of this disease.”

Summary of Results

Dr. Conlin reported on eight patients with HER2+ metastases to the skin who received the maximum tolerated tucatinib dose in combination with capecitabine and/or trastuzumab from the Company’s Phase 1b combination study. All patients in this study had previously been treated with trastuzumab, a taxane, and T-DM1. Most patients had also received lapatinib, pertuzumab, and/or radiotherapy to the skin. Patients had previously received a median of six lines of drug therapy.

Overall systemic clinical responses reported in this patient population included one complete response, three partial responses and four with stable disease. Responses observed in skin lesions in these patients included one complete response, four partial responses and three patients with stable disease, including one partial response of a patient receiving tucatinib and trastuzumab only.1 Tucatinib was previously reported to be well tolerated by patients in the Phase 1b combination studies, with a manageable adverse event profile.

“We’re pleased to see continued evidence of systemic clinical activity with tucatinib in combination therapy, including in patients with difficult-to-treat metastases such as these,” commented Luke N. Walker, MD, Vice President, Clinical Development, Cascadian Therapeutics. “This potential benefit of tucatinib for patients with skin metastases is an interesting finding that we will continue to monitor.” (Original Source)

Shares of Cascadian Therapeutics closed last Friday at $1.49, down $0.07 or -4.49%. CASC has a 1-year high of $1.83 and a 1-year low of $0.82. The stock’s 50-day moving average is $1.28 and its 200-day moving average is $1.16.

On the ratings front, CASC stock has been the subject of a number of recent research reports. In a report issued on August 8, Cowen analyst Boris Peaker reiterated a Buy rating on CASC. Separately, on June 15, Cantor’s Mara Goldstein reiterated a Hold rating on the stock and has a price target of $2.00.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Boris Peaker and Mara Goldstein have a total average return of 16.8% and 2.1% respectively. Peaker has a success rate of 50.0% and is ranked #141 out of 4183 analysts, while Goldstein has a success rate of 42% and is ranked #1311.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its current clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts